XPA

DNA repair protein complementing XP-A cells

697 patent compounds predicted against XPA, 518 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29524569	0.85	18/20
SCHEMBL19654559	0.85	18/20
SCHEMBL29388794	0.85	18/20
SCHEMBL19654076	0.85	18/20
SCHEMBL29385593	0.85	18/20
SCHEMBL29388116	0.85	18/20
SCHEMBL30679196	0.85	17/20
SCHEMBL30679197	0.85	17/20
SCHEMBL29385900	0.85	17/20
SCHEMBL29388482	0.84	17/20
SCHEMBL19644258	0.76	17/20
SCHEMBL19644259	0.76	17/20
SCHEMBL20847992	0.76	17/20
SCHEMBL29524675	0.75	17/20
SCHEMBL29385646	0.72	17/20
SCHEMBL19644199	1.00	16/20
SCHEMBL19644200	1.00	16/20
SCHEMBL19644318	1.00	16/20
SCHEMBL19644341	1.00	16/20
SCHEMBL19644342	1.00	16/20

Germline variants in XPA on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full XPA gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to XPA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer	PHASE2	UNKNOWN
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma	PHASE1/PHASE2	RECRUITING
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer	PHASE1/PHASE2	RECRUITING
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)	PHASE2	COMPLETED
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction	PHASE2	COMPLETED
Selinexor, Cyclophosphamide and Prednisone in Myeloma	PHASE2	COMPLETED
Satraplatin and Prednisone to Treat Prostate Cancer	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	PHASE1	COMPLETED
A Trial of Selinexor, Ruxolitinib and Methylprednisolone	PHASE1	RECRUITING
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers	PHASE1	RECRUITING
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Treatment of Chronic Lymphocytic Leukemia	nan	UNKNOWN
XPAND Trial: Enhancing XP Photoprotection Activities - New Directions	nan	COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Natural History Study for DNA Repair Disorders	nan	RECRUITING
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）	nan	RECRUITING
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.	nan	UNKNOWN
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate	nan	COMPLETED
Aerobic Exercise and Telomere Length in Patients With Heart Failure.	nan	UNKNOWN
Efficacy and Adverse Effects of Olaparib in Ovarian Cancer.	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates	nan	COMPLETED
Telomere Repair Gene Mutation in Inflammatory Bowel Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a XPA binder may also engage these)

Protein	Name	Similarity
Q64267	—	0.999	Q64267 →
P27088	—	0.998	P27088 →
P27089	—	0.987	P27089 →
MNAT1	CDK-activating kinase assembly factor MAT1	0.979	landscape →
O08837	—	0.975	O08837 →
Q8N806	—	0.975	Q8N806 →
Q2KJC1	—	0.975	Q2KJC1 →
P92948	—	0.975	P92948 →
E1C760	—	0.975	E1C760 →
Q8K339	—	0.974	Q8K339 →
Q6PFL6	—	0.974	Q6PFL6 →
Q69ZX6	—	0.973	Q69ZX6 →
Q5RAD5	—	0.973	Q5RAD5 →
Q6A068	—	0.973	Q6A068 →
Q5ZJ85	—	0.973	Q5ZJ85 →
Q91WR3	—	0.973	Q91WR3 →
Q2KIA6	—	0.973	Q2KIA6 →
Q3UJB0	—	0.973	Q3UJB0 →
Q6U6G5	—	0.973	Q6U6G5 →
A2AQ19	—	0.973	A2AQ19 →
Q1RMM1	—	0.972	Q1RMM1 →
CDC5L	Cell division cycle 5-like protein	0.972	landscape →
Q2IBC3	—	0.972	Q2IBC3 →
Q9Z315	—	0.972	Q9Z315 →
Q922U1	—	0.972	Q922U1 →
Q6PII3	—	0.972	Q6PII3 →
Q8N1G2	—	0.972	Q8N1G2 →
PRPF3	U4/U6 small nuclear ribonucleoprotein Prp3	0.972	landscape →
Q9CWV6	—	0.971	Q9CWV6 →
Q99PL6	—	0.971	Q99PL6 →